KPV vs Larazotide
Both KPV and Larazotide are used for gut-health. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →Larazotide
Evidence B+Larazotide Acetate (AT-1001)
An 8-amino-acid oral peptide that tightens intestinal tight junctions by antagonizing zonulin signaling. The most-studied 'leaky gut' peptide with celiac trial data.
View full Larazotide profile →Side-by-Side
| Attribute | KPV | Larazotide |
|---|---|---|
| Evidence Grade | C+ | B+ |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — Phase 3 completed for celiac disease (results mixed) |
| Typical Dose | 200–500 mcg orally or topical (research only) | 0.5 mg three times daily before meals (oral) |
| Clinics Indexed | 26 | 33 |
| Categories | anti-inflammatory, gut-health, skin | gut-health |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — Larazotide
- ✓Tight-junction restoration
- ✓Intestinal permeability reduction
- ✓Celiac symptom reduction
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.